List of Contract Research Companies in China - 19

Founded in 2023 and based in Shanghai, China, Allink Biotherapeutics is a biotech company dedicated to expediting the development of a diverse pipeline of FIC/BIC therapeutic candidates for oncology and immune diseases. Our goal is to harness our proprietary bispecific antibody and ADC technology platforms, along with efficient execution and business collaboration , to address critical unmet clinical needs.

Shanghai APTBIO Biotechnology Co., Ltd. was founded in 2004. Its predecessor was the external service platform of the Proteomics Research and Analysis Center of the Shanghai Institutes for Life Sciences, Chinese Academy of Sciences. Through technical cooperation with domestic and foreign high-level research institutions and the innovative ability of its own R&D team, the company has established an enterprise innovation institute, established a large cohort multi-omics research technology platform, a biological drug early research and preclinical CMC research and analysis platform, a biological drug and medical device registration and approval platform, and AI big data algorithm. It has laid out three business sectors: technology services, biopharmaceuticals, and big health consumer medical CRO services, and has built a life science and big health business map that combines AI big data with mass spectrometry multi-omics technology applications.

Bio Bench co. ltd (www.bio-bench.com, Belgium and China) is aCRO (Contract Research Organization) that develops functionalantibodiesand bio-active proteins for drug discovery, in-vitro diagnostickits and biologicalresearch.

who are we : Chempartner is an innovative company adhering to the principle of "Science First, Technology Leads," providing integrated services for pharmaceutical research and production (CRO+CDMO). It has developed advanced technological capabilities, assembled top-tier scientists, and equipped itself with state-of-the-art research, animal testing, and pharmaceutical intermediate production facilities. Vision Statement： We strive to ensure that all drugs can be produced and every disease can be addressed by creating an open-access platform equipped with the most advanced capabilities and technologies in the global pharmaceutical sector. Mission Statement Our goal is to revolutionize and expedite the discovery, development, and manufacturing of pharmaceuticals. By providing a comprehensive open-access platform, we empower our global healthcare partners and improve patient outcomes around the world. Our PROUD Culture Passion: Committed to customer satisfaction, continuous innovation, and a vibrant, energetic workplace. Responsibility: Embracing accountability, handling challenging tasks with integrity, and contributing to the community. Open Culture: Promoting teamwork, diversity, inclusion, and transparent communication. R&D Focus: Prioritizing research and development, advancing scientific excellence, and fostering innovation.

Harvest Integrated Research Organization (HiRO) is a globally oriented, innovative clinical research organization (CRO). With global operations and integrated capabilities, HiRO provides a full range of cross-border solutions and services to its clients, including early pre-clinical strategic planning, clinical trial design, regulatory affairs, pharmacovigilance, statistics, data management, end-to-end project management, and clinical and medical monitoring services. As an emerging global CRO, HiRO strives to become a market-leading, integrated global clinical research organization that works collaboratively with biotech and pharmaceutical companies to bring new products from the laboratory to the market, providing more effective solutions for patients worldwide.

HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com

ICE Bioscience was founded in 2010 as an Innovative CRO+ Explorer company. We specialize in early drug discovery services, spanning from target validation to the identification of pre-clinical candidates. Currently, ICE Bioscience offers a broad selection of off-the-shelf assays, including 100+ ion channels, 800+ Kinases/enzymes, 100+ GPCRs, and 40+ nuclear receptor assays, all accompanied by validation data and screening information. This comprehensive range of assays provides us with a competitive edge, as it covers a vast majority of druggable targets. Our company has established multiple platforms, encompassing Protein Engineering, Cell Line Development, Target Based Assays, Safety Pharmacology, Translational Biology, DMPK, In Vivo Pharmacology and Biophysical Assays, enabling us to smoothly execute the DMTA cycle (Design-Make-Test-Analysis cycle) for innovative drug discovery in collaboration with our clients.

KMD Bioscience is a biotech company located in Tianjin, China. Our CRO services&products cover antibody engineering(recombinant antibodyproduction, antibody sequencing&purification), protein production, expressionand purification and other services related to phage display, stable cell lineconstructionand peptide.

LIDE (Lab for Innovated Diagnosis and Experimental Therapeutics) is a translational medicine service provider with 10 years of delivering innovations in oncology translational research and immuno oncology. Founded in 2011 by overseas returnees Drs. Danyi Wen, Yizhun Zhu, et al, LIDE brings together first-class research and management teams with advanced scientific backgrounds to push the frontier of translational medical research. We operate at the forefront of new technologies and adopt the highest international accreditation standards. LIDE offers traditional CRO services like NGS, CR (conditionally reprogrammed) cell lines and has a collection of more than 1500 patient derived xenograft (PDX) models covering 40+ cancer types, of which 200+ are special drug resistant and/or genetically altered. More importantly, LIDE specializes in using its proprietary MiniPDX and Kcell Assay Kit to offer Functional Diagnosis - an evolved approach to drug r&d that maximizes budget efficiency and minimizes time to validation. LIDE differentiates itself from other CROs by continually conducting self-funded internal research of its immense tumor bio bank, and working with KOLs in the academic space to vigorously promote the development and application of translational medical research in China. We also adopt the highest international operational standards. The company owns AAALAC accredited SPF level Animal Centers, safety level 2 laboratories and world-class, state of the art equipment.

Mido (Nanjing) Biotechnology Co., Ltd. is the first molecular imaging pharmaceutical research and development outsourcing (MI-CRO) company in China. The company leverages the world’s most advanced radiolabeling and in vivo molecular imaging technologies to provide domestic and international clients with comprehensive solutions and outsourced technical services for new drug R&D, including drug screening, biodistribution, pharmacokinetic research, and pharmacodynamic evaluation. Its business spans translational research from nude mice, rats, and monkeys to humans, focusing on major diseases such as cancer, coronary heart disease, Alzheimer’s disease, Parkinson’s disease, epilepsy, rheumatism, and diabetes, as well as cutting-edge fields involving receptors, genes, and stem cells. It explores disease mechanisms, develops diagnostic and therapeutic drugs, and evaluates therapeutic outcomes. PET molecular imaging offers unique advantages—such as in vivo imaging, dynamic quantification, self-control, and continuous observation—that significantly shorten the drug development cycle, reduce the risk of failure, and accelerate the introduction of new drugs to the market. 米度（南京）生物技术有限公司是国内首家分子影像医药研发外包（MI-CRO）企业。公司利用世界先进的放射标记示踪（Radiolabeling）和活体分子显像（Molecular imaging）技术为海内外客户提供药物筛选、生物分布、药代动力学研究、药效学评价等新药研发整体解决方案和外包技术服务，业务贯穿从裸（小）鼠、大鼠、猴子到人体的转化研究，重点针对肿瘤、冠心病、老年痴呆、帕金森、癫痫、风湿免疫、糖尿病等重大疾病以及受体、基因、干细胞等前沿研究领域，探寻疾病机理、开发诊疗药物、评价治疗效果。PET 分子影像具有活体显像、动态定量、自身对照、连续观察等突出优点，大大缩短药物研发周期、降低失败风险、加快新药上市。

About Us As a contract research organization (CRO) in pharmaceutical R&D and clinical studies, Panacro Pharmaceutical Technology Co., Ltd. is committed to providing overall solutions for clinical studies & IND and NDA of chemical & biological drugs and vaccines. Since its establishment in 2004, Panacro has provided professional technical services to hundreds of customers at home and abroad in 20+ major therapeutic fields. In addition, it established offices in 20 major provinces or cities in China. With complete and detailed standard operating procedures (SOPs), and a professional team operating in accordance with international standards (ICH-GCP), it has built close cooperation with 80% study sites in China. Panacro focuses on providing customers with quality and efficient professional services, in order to shorten the product marketing cycle, and facilitate the product marketization. By virtue of a professional technical team and an operation team operating in strict accordance with relevant standards, as well as professional and efficient quality service, we provide customers with highly customized solutions in a rigorous and pragmatic way based on the principle of sincere cooperation and honest operation.

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

An Unique TIDEs Platform with Cutting Edge Technologies As an industry leader in therapeutic peptides, Sinopep stands as the exclusive API supplier for Albuvirtide and Lanreotide 505b2—two of the top five in-demand peptide products. We are also the global leader in supplying Semaglutide, Tirzepatide, and Liraglutide, dominating the market in export quantity. Sinopep consistently delivers the highest quality peptide APIs, supported by comprehensive documentation that meets stringent global standards. Our advanced process development and manufacturing technologies ensure efficient production with high yields and some of the largest batch sizes in the industry. Additionally, Sinopep excels in providing efficient, flexible, and high-quality end-to-end CRDMO services across multiple modalities, including peptides, oligonucleotides, small molecules, and related synthetic conjugates. This makes Sinopep a trusted partner in the pharmaceutical and healthcare industries worldwide.

SinoTherapeutics is a specialty pharma focus on the R&D, registration, manufacture and commercialization of complex generic products as well as innovative formulation products (505B2). The company aims to achieve commercialize its product globally, and to provide cost-effective high-quality products to international markets

VectorBuilder offer gene delivery technologies. VectorBuilder offers a full spectrum of gene delivery solutions covering virtually all research and clinical needs from bench to bedside

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

公司的主营业务为特色原料药、医药中间体的研发、生产和销售，以及为客户提供定制加工和研发业务。产品具有手性结构多、研发难度大、技术壁垒高、生产工艺独特等特点。公司是高新技术企业，被认定为“省级高新技术企业研究开发中心”、“省级企业研究院”，公司拥有院士工作站、博士后工作站、博士后创新实践基地等优秀的研发平台，与诸多高校、研究所保持良好的研发合作关系。

自由能计算，化学结构预测；小分子对接；小分子对接计算或者模拟 计算化学，Python ，分子对接，机器学习，数据模型，人工智能，分子对接软件，Amber 软件，Autodock，Schrodinger, MOE，Gaussian 软件，tensorflow, Git, GitHub. 数据分析和建模"，"化学信息学"，"生物信息学"，"量子化学"，"计算化学软件开发"